InvestSMART

Vectus Biosystems Limited (ASX: VBS) - Announcements

Current share price for VBS : $0.075 0.004 (5.06%)+

ASX company news and announcements for Vectus Biosystems Limited (VBS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Vectus Biosystems Limited (VBS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Vectus Biosystems Limited (VBS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Vectus Biosystems Limited (VBS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5 Appendix 2A - Issue of Shares 15 Feb 2022 3:56PM $1.400 $0.075 fallen by 94.64%
$5 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2022 8:07AM $1.350 $0.075 fallen by 94.44%
$5 Results of Annual General Meeting 25 Jan 2022 2:09PM $1.250 $0.075 fallen by 94%
$5 Chairman & CEO Address to Shareholders 25 Jan 2022 10:14AM $1.260 $0.075 fallen by 94.05%
$5 Notice of Annual General Meeting / Proxy Form 23 Dec 2021 6:03PM $1.250 $0.075 fallen by 94%
$5 Date of Annual General Meeting 17 Dec 2021 8:21PM $1.200 $0.075 fallen by 93.75%
$5 Third S.A.D. Group Reviewed By Trial Safety Review Committee 29 Nov 2021 10:00AM $1.450 $0.075 fallen by 94.83%
$5 Change of Director's Interest Notice - RS 15 Nov 2021 11:28AM $1.420 $0.075 fallen by 94.72%
$5 Appendix 2A - Issue of Shares 11 Nov 2021 8:28AM $1.650 $0.075 fallen by 95.45%
$5 Investor Webinar 8 Nov 2021 2:28PM $1.650 $0.075 fallen by 95.45%
$5 Progress Presentation 8 Nov 2021 2:16PM $1.650 $0.075 fallen by 95.45%
$5 Quarterly Activities Report & Appendix 4C 29 Oct 2021 8:15AM $1.770 $0.075 fallen by 95.76%
$5 Corporate Governance Statement & Appendix 4G 25 Oct 2021 4:02PM $1.900 $0.075 fallen by 96.05%
$5 Annual Report to shareholders 25 Oct 2021 3:56PM $1.900 $0.075 fallen by 96.05%
$5 Response to ASX Price and Volume Query 19 Oct 2021 4:28PM $2.000 $0.075 fallen by 96.25%
$5 Appendix 2A - Issue of Shares 7 Oct 2021 8:25PM $1.470 $0.075 fallen by 94.90%
$5 Broker Briefing Investor Webinar 7 Sep 2021 5:59PM $1.390 $0.075 fallen by 94.60%
$5 Update on Phase I Human Trial 7 Sep 2021 9:37AM $1.360 $0.075 fallen by 94.49%
$5 Full Year Statutory Accounts 31 Aug 2021 6:33PM $1.320 $0.075 fallen by 94.32%
$5 Preliminary Final Report - Appendix 4E 31 Aug 2021 6:20PM $1.320 $0.075 fallen by 94.32%
$5 Progress Presentation 30 Aug 2021 1:50PM $1.350 $0.075 fallen by 94.44%
$5 Successful Completion of First Group in Phase I Human Trial 23 Aug 2021 9:42AM $1.230 $0.075 fallen by 93.90%
$5 Quarterly Activities Report & Appendix 4C 30 Jul 2021 8:37AM $1.170 $0.075 fallen by 93.59%
$5 Approval Received for Phase I Trial in Australia 17 Jun 2021 8:23AM $1.010 $0.075 fallen by 92.57%
$5 Appendix 3G - Issue of Options under EIP 27 May 2021 11:45AM $0.980 $0.075 fallen by 92.35%

176 - 200 of 339 results

Page 8 of 14

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.